article thumbnail

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics

Fierce Pharma

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics aliu Thu, 03/30/2023 - 16:18

article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO

Fierce Pharma

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO fkansteiner Tue, 03/21/2023 - 09:41

article thumbnail

US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug Hetlioz

Fierce Pharma

The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. | The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S.

article thumbnail

Exscientia trims pipeline to focus on top cancer prospects

pharmaphorum

Exscientia trims pipeline to focus on top cancer prospects Phil.Taylor Tue, 03/10/2023 - 12:09 Bookmark this

article thumbnail

AbbVie’s new drugs keep post-Humira prospects on track

pharmaphorum

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

article thumbnail

Launch Readiness 2023: Key trends impacting pharma product launches

Tribeca Knowledge

I n our latest report, Launch Readiness 2023, we look at the prospects and challenges for new medicines entering the market in the shadow of COVID-19.

Pharma 97